Developing a robust process for protein production is critical for your vaccine or biotherapeutic development. ExpreS2ion has developed a number of processes that have been successfully transferred to commercial manufacturers. Through process development, we can considerably increase the protein yield, which reduces manufacturing costs.
We develop high-expressing monoclonal cell lines and robust processes. We support transfer to cGMP facilities. The robust ExpreS2 platform allows for various process modalities and intensification. This is why we have developed batch, fed-batch and perfusion processes using conventional bioreactors or single-use bioreactors. The characteristic robustness of the ExpreS2 system provides extra flexibility when transferring processes to cGMP facilities.
To find out more about how we can support your process development, please give us a call.